Introduction
Over the past decade, advances in therapeutic approaches have improved the outcome for patients with acute myeloid leukemia (AML). About 75% of patients under 65 years and about 50% of elderly patients achieve a complete remission, cytomorphologically defined as the presence of less than 5% blast cells in the bone marrow (BM). However, many patients relapse, implying that treatment does not kill all AML cells and that surviving cells remain undetected by the use of cytomorphology. To trace low frequencies of remaining leukemic cells, ie 'minimal residual disease' (MRD), more sensitive methods are required. MRD techniques should reach sensitivities of at least 10 −3 (one leukemic cell in 1000 normal cells), but sensitivities of 10 −4 to 10 −6 are preferred. 1 Flow cytometric immunophenotyping and polymerase chain reaction (PCR) techniques are able to detect such low frequencies of leukemic cells. Detection of MRD by flow cytometry is based on the presence of aberrant phenotypic features of the AML cells that allow them to be distinguished from normal cells. 2 Monitoring of MRD by PCR techniques is based on the detection of clone-specific sequences, such as junctional regions of immunoglobulin (Ig) and T cell receptor (TCR) genes or on the detection of leukemia-specific breakpoint fusion gene transcripts of chromosome aberrations.
Junctional regions of Ig and TCR gene rearrangements are the result of recombination of different variable (V), diversity (D), and joining (J) gene segments with deletions and random insertions of nucleotides at the coupling sites of the gene segments. This lymphoid-specific process is mediated via V(D)J recombinase activity, wherein the recombination activating gene products (RAG1 and RAG2) play a crucial role. Clonal patient-specific Ig and TCR gene rearrangements can be identified in the vast majority of pediatric and adult patients with acute lymphoblastic leukemia (ALL). 3, 4 Cross-lineage Ig and TCR gene rearrangements have been reported in AML patients as well. Results from the literature reveal that Ig heavy chain (IGH) gene rearrangements occur in 4 to 18% of AML patients, whereas Ig kappa light chain (IGK) gene rearrangements occur in 1 to 5% only. [5] [6] [7] [8] [9] [10] So far, only one AML case has been reported having rearrangements of the Ig lambda (IGL) locus. 10 Rearrangements of the TCR gamma (TCRG) and TCR delta (TCRD) genes have both been found in 4 to 14% of cases. [9] [10] [11] [12] Several types of PCR-detectable chromosome aberrations are relatively frequently found in AML: t(8;21)(q22;q22) occurs in 6-8% of adult AML and 10-14% of childhood AML and can especially be found in the AML-M2 subtype; inv(16)(p13;q22) occurs in 5-7% and is closely associated with the AML-M4Eo subtype; t(15;17)(q22;q21) is found in 5-10% of AML and is exclusively found in acute promyelocytic leukemia (AML-M3); about 5% of de novo AML have 11q23 abnormalities involving the MLL gene, such as t(4;11)(q21;q23) and t(9;11)(p22;q23). [13] [14] [15] However, t(9;22)(q34;q11) is rarely found in AML. 15 Chromosome aberrations can be used for risk group classification: 11q23 aberrations are associated with poor prognosis, whereas t(8;21), t(15;17) and inv (16) are associated with relatively good prognosis. 16, 17 Since previous studies mainly focused on the detection of either chromosome aberrations or Ig/TCR gene rearrangements, we now investigated the occurrence of both types of MRD-PCR targets in a large group of 105 consecutive AML patients. The aim of the study presented here was two-fold:
(1) precise characterization of the type of Ig/TCR gene rearrangements that occur in AML patients; and (2) analysis of whether Ig/TCR gene rearrangements and chromosome aberrations with fusion gene transcripts are complementary PCR targets for MRD studies. Additionally, we developed a 'real-time' quantitative polymerase chain reaction (RQ-PCR) using TaqMan technology for the analysis of RAG1 and RAG2 gene expression levels in AML patients, as a potential tool for selection of AML samples with Ig/TCR gene rearrangements.
Materials and methods

Patients and cell samples
Peripheral blood (PB) or BM samples from 105 consecutive AML patients (81 adults and 24 children) were obtained at initial diagnosis. The diagnosis of AML was based on cytomorphology, cytochemistry, and flow cytometric immunophenotyping. Myeloid blast crises of chronic myeloid leukemia were excluded from the study. Patients were classified according to the revised French-American-British (FAB) criteria. 18 Mononuclear cells (MNC) were isolated by Ficoll-Paque centrifugation (density: 1.077 g/cm 3 ; Pharmacia, Uppsala, Sweden) and stored in liquid nitrogen.
Additional molecular analysis was performed on five previously described AML patients with Southern blot-detectable Ig/TCR gene rearrangements of which DNA was still available. 9 Three other patients from this previous study could not be further investigated due to lack of DNA.
Reverse transcriptase polymerase chain reaction (RT-PCR)
Total RNA was isolated from cryopreserved MNC by phenolchloroform extraction. 19 RT-PCR was performed on all 105 AML patients as previously described. 15 Samples were investigated for the presence of six fusion gene transcripts associated with well-defined chromosome aberrations: AML1-ETO, CBFB-MYH11, PML-RARA, BCR-ABL p190 and p210 and MLL-AF4. Quality of RNA was checked by amplification of ABL gene transcripts. A single PCR was performed in a volume of 50 l using 2 l of cDNA. The sequences of the primers used for PCR amplification were developed during the BIOMED-1 Concerted Action. 15 PCR conditions comprised: initial denaturation at 95°C for 30 s, followed by 35 cycles of 30 s at 94°C, 60 s at 65°C and 60 s at 72°C using a Perkin Elmer 9600 thermal cycler (Applied Biosystems, Foster City, CA, USA). Appropriate positive and negative controls were used in all experiments. 15 
Southern blot analysis of Ig/TCR gene rearrangements
Screening for IGH, IGK, and TCRD gene rearrangements was done by Southern blot analysis. DNA was isolated from frozen MNC fractions using the QIAamp Blood Kit (Qiagen, Chatsworth, CA, USA). 20 Fifteen g of DNA was digested with BglII (Gibco, Paisley, UK), size-separated in 0.7% agarose gels, and transferred by vacuum blot to Nytran-13N nylon membranes (Schleicher and Schuell, Dassel, Germany), as described. 21 The membranes were hybridized with 32 P-random oligonucleotide-labeled probes. The IGH gene configuration was analyzed with the IGHJ6 probe (DAKO, Carpinteria, CA, USA), 22 IGK gene rearrangements were analyzed with the IGKJ5 and IGKDE probes (DAKO), 23 and the TCRD gene configuration was analyzed with the TCRDJ1, TCRDJ3 and TCRDV2 probes (DAKO). 24 Appropriate analysis of TCRG gene rearrangements can not Leukemia be performed on BglII restricted DNA. 25 Because of limited availability of DNA, an additional digest with EcoRI (Gibco) was only performed in patients, who showed clonal TCRG gene rearrangements by PCR heteroduplex analysis (see below). The TCRG gene configuration in these patients was analyzed with the TCRGJ13 probe (DAKO). 25 
PCR heteroduplex analysis of Ig/TCR gene rearrangements
Only patients who showed rearrangements and/or deletions of IGH, IGK and/or TCRD genes on Southern blot were further investigated by PCR heteroduplex analysis for these genes. Southern blotting for detection of TCRG gene rearrangements was performed in a limited number of patients, but PCR heteroduplex analysis was performed in all patients. All relevant PCR analyses were also performed on the five AML samples from a previous Southern blot study, which showed Ig/TCR gene rearrangements. 9 PCR was essentially performed as described previously. 26 Briefly, in each 50 l PCR reaction, 50 ng DNA sample, 6.25 pmol of the 5′ and 3′ oligonucleotide primers and 1 U AmpliTaq Gold polymerase (Applied Biosystems) were used. The sequences of the oligonucleotides used for amplification of IGH, IGK, TCRG and TCRD gene rearrangements were described elsewhere.
26,27 PCR conditions comprised: initial 10 min at 94°C, followed by 35 cycles of 45 s at 92°C, 90 s at 60°C and 2 min at 72°C using a Perkin-Elmer 480 thermal cycler (Applied Biosystems). A final extension step of 10 minutes at 72°C was performed after the last cycle. Appropriate positive and negative controls were used in all experiments. 26 To confirm clonality of the PCR-amplified rearrangements, heteroduplex analysis was performed on positive PCR products. 28 PCR products were denaturated at 94°C for 5 min and subsequently cooled at 4°C for 60 min to induce duplex formation. The duplexes were immediately loaded on a 6% non-denaturating polyacrylamide gel in 0.5 × Tris-boric acid-EDTA (TBE) buffer, run at room temperature and visualized by ethidium bromide staining. A 100-bp DNA ladder (Promega, Madison, WI, USA) was used as size marker.
Sequence analysis of Ig and TCR gene rearrangements
PCR products found to be clonal by heteroduplex analysis were directly sequenced, except for cases in which PCR heteroduplex analysis showed more than two clonal bands. In such cases, homo-or heteroduplex bands were excised from the polyacrylamide gel and eluted as described before. 27 The eluted PCR products were sequenced directly. Sequencing was performed using the BigDye terminator cycle sequencing kit with AmpliTaq DNA polymerase on an ABI PRISM 377 automated sequencer (Applied Biosystems). Briefly, 50 to 200 ng of PCR product, 3.2 pmol primer and 5 l BigDye terminator mix were used in a 15 l reaction volume. The cycling protocol was 96°C for 30 s, followed by 60°C for 4 min for a total of 25 cycles. All rearrangements were sequenced in two directions from two independent PCR products.
Interpretation of sequence data
V, D and J gene segments in TCRG and TCRD rearrangements were identified as described previously. 29 The Ig sequences 
Real-time quantitative PCR (RQ-PCR) of RAG gene expression levels
Based on germline RNA sequences of the human RAG1 and RAG2 genes, primers and TaqMan probes were designed using Primer-Express software (Applied Biosytems) according to the manufacturer's guidelines. RAG1: forward primer 5′-TGAGTAATATCAACCAAATTGCAGACA-3′, reverse primer 5′-GGATCTCACCCGGAACAGC-3′, TaqMan probe 5′-CCCC AGATGAAATTCAGCACCCACATATTAA-3′; RAG2: forward primer 5′-GTTTAGCGGCAAAGATTCAGAGA-3′, reverse primer 5′-GTCCATCAAAATTCATCAGTGAGAA-3′, TaqMan probe 5′-CAAAAATCTACGTACCATCAGAAACTATGTCTCT GCA-3′ (Applied Biosystems).
Fifty l reaction mixtures contained Universal Master Mix 2× (Applied Biosystems), 900 mm primers, 200 mm probe and approximately 100 ng of RNA (6 l cDNA). RQ-PCR experiments were performed in duplicate and consisted of 2 min at 50°C, 10 min at 95°C, followed by 50 cycles of 15 s at 95°C and 1 min at 60°C. Real-time detection of obtained PCR products was based on TaqMan technology using the ABI PRISM 7700 Sequence Detection System (Applied Biosystems). Nontemplate controls (NTC) and thymocyte DNA were used as negative controls in each RAG1/RAG2 RQ-PCR experiment. In all cases, thymocyte DNA did not result in any amplification, indicating that RAG1 and RAG2 mRNA was specifically detected by our RQ-PCR method. A standard curve was established using a dilution series of thymocyte RNA (10 −1 to 10 −6 ) in cell line RNA (HL-60). As HL-60 cells do not express RAG1 or RAG2, HL-60 cDNA was taken as a control in each experiment and was always negative. To correct for differences in the amount of total RNA added to a reaction, the copy number was normalized to the GAPDH housekeeping gene (Applied Biosystems kit). The GAPDH assay was confirmed to be RNA specific, as thymocyte DNA included in each experiment was always negative. RQ-PCR data of RAG1 and RAG2 were subsequently corrected for the tumor load of the sample as determined by flow cytometric immunophenotyping. Kronecker product of two unstructured covariance matrices (one for sample origin, and one for the type of RAG gene) was used. The alpha-level 0.05 was used. All analyses were performed with the SAS-procedure PROC MIXED (version 8.1).
Statistical analysis
Results
Detection of fusion gene transcripts in AML patients
Of 105 AML patients, 17 harboured chromosome aberrations (16%) (4/24 pediatric patients and 13/81 adults) as detected by RT-PCR analysis. Six patients (four children and two adults) had an AML1-ETO fusion gene transcript (5.7%): four concerned AML-M2, one AML-M4 and one AML-M1. CBFB-MYH11 fusion gene transcripts were detected in six cases (5.7%); all six concerned the predominant type A fusion gene transcript. 15 Five of these six leukemias were classified as an AML-M4Eo and one as AML-M5. Three cases with PML-RARA fusion gene transcripts were found (2.9%): all these patients had an AML-M3 morphology. In two adult AML patients (1.9%), a BCR-ABL fusion gene transcript was identified: one encoded the 210 kDa fusion protein and one the smaller 190 kDa BCR-ABL protein. They corresponded with an AML-M0 and an AML-M4, respectively. An MLL-AF4 fusion gene transcript was not found in this series. In the additional series of five AML patients from our previous study, 9 no fusion gene transcripts were detected by RT-PCR.
Detection of Ig/TCR rearrangements in AML
Ninety-five AML patients (74 adults and 21 children) were subjected to Southern blot analysis of the IGH, IGK and TCRD gene loci. Ten patients could not be studied because of insufficient amounts of DNA; coincidently, four of these 10 patients contained a fusion gene transcript. This is in contrast to only 13 of the 95 patients (14%), which were studied for Ig/TCR gene rearrangements.
IGH gene rearrangements were detected by Southern blotting in 5/95 AML patients (5%): two children and three adults (Figure 1 ). Monoallelic IGH gene rearrangements were found in three out of five patients (P-26, A-16 and A-34) and biallelic rearrangements were observed in case P-08. Southern blot analysis of patient A-62 showed three rearranged bands of different densities, suggesting the formation of subclones. Detailed PCR heteroduplex analysis of the IGH locus in the five patients with IGH gene rearrangements on Southern blot, detected seven clonal homoduplexes: one complete V H -J H rearrangement (patient P-08) and six incomplete D H -J H rearrangements ( (Table 1) .
IGK gene rearrangements were found in only one patient (P-08): hybridization with the IGKJ5 probe showed a deletion, whereas hybridization with the IGKDE probe revealed a rearranged band. All other AML patients displayed the IGK
Figure 1
Southern blot analysis of the IGH gene in three pediatric and four adult AML patients. Control DNA and DNA from the seven AML patients were digested with BglII, size separated and blotted on to nylon membrane filters, which were hybridized with the 32 P-labeled IGHJ6 probe. The IGH gene was rearranged in five out of the seven patients presented and a germline configuration was present in two patients (P-20 and A-38). Rearrangement of the IGH gene locus on one allele was found in three patients (A-16, A-34 and P-26) and on both alleles in one patient (P-08). In patient A-62, more than two rearranged IGH gene bands of different density were visible, suggesting the presence of subclones. locus in germline configuration. PCR heteroduplex analysis of patient P-08 showed a VIII-Kde rearrangement. The size of this PCR product appeared to be approximately 800 bp on agarose instead of the expected 429 bp (Figure 2) . Sequence analysis revealed a complex rearrangement in which the V3.20 gene segment was coupled to the J3, followed by the intronic sequence until the RSS of J4. The J4 gene segment itself was absent, yet another junctional region, followed by Kde was found (Table 1) . So, this seemingly VIII-Kde rearrangement is in fact a J4-Kde rearrangement.
Analysis of the TCRD gene configuration in the 95 samples demonstrated rearrangements and/or deletions of this locus in three pediatric cases (P-08, P-20 and P-24). By PCR heteroduplex analysis, clonal TCRD PCR products were found in two patients: in patient P-08, the rearrangement consisted of a complete V␦2-D␦3-J␦1 joining, whereas in patient P-20 an incomplete D␦2-D␦3 rearrangement was identified. In patient P-24 both TCRD alleles were deleted.
TCRG gene rearrangements were generally not analyzed by Southern blotting, due to limited availability of DNA. Hence PCR heteroduplex analysis of TCRG was performed in all 95 AML patients (74 adults and 21 children). Four monoclonal rearrangements were found in three patients (A-25, A-38 and P-08). Subsequent direct sequence analysis of PCR products elucidated that in these four rearrangements the V␥II (V␥9) or V␥III (V␥10) gene segment was joined to the J␥2.3 gene segment. By Southern blotting, no rearranged bands of TCRG gene locus could however be detected in these three patients, indicating that all four clonal PCR products were probably derived from small subclones. The junctional regions of all identified Ig and TCR gene rearrangements showed deletions as well as insertions (Table 1) .
Leukemia
Taking the Southern blot and PCR heteroduplex analysis data together, major cross-lineage IGH, IGK and/or TCRD gene rearrangements occurred in only 6/95 AML patients (Table 1 ). In only one patient (P-20) a fusion gene transcript (AML1-ETO) was also found. Therefore, at least one reliable PCR target was available for MRD detection in 18 out of 95 AML patients (19%).
Identification of Ig/TCR gene rearrangements in an additional series of five AML patients
In our previous study, 9 8 For the TCRD gene locus, a V␦2-D␦3 rearrangement was detected in patient RS by Southern blot analysis and confirmed by PCR heteroduplex analysis in this study. The other rearranged allele in this patient could not be identified. In patient PM, Southern blot analysis showed one rearranged allele. Using the D␦2-J␦1 primer combination, two heteroduplexes and co-migrating homoduplexes were found by PCR heteroduplex analysis. Sequence analysis allowed us to identify both heteroduplexes (Table 1) .
Biallelic rearrangements of the TCRG locus were found in two patients of the previous study. 9 PCR heteroduplex analysis allowed us to identify a V␥I-J␥2.3 and a V␥IV-J␥2.1 joining in patient PM, whereas only one of the two TCRG gene rearrangements found by Southern blot could be identified in patient RS (V␥IV-J␥2.3) ( Table 1) .
Association of Ig/TCR gene rearrangements with patient and disease characteristics
AML patients with Ig/TCR gene rearrangements and patients without Ig/TCR gene rearrangements were compared for their patient and disease characteristics (age, sex, FAB subtype and immunophenotype). Cytogenetic findings could not be included, since these data were incomplete. Results showed that two associations were statistically significant. Firstly, in the patient group of 16 to 60 years, the frequency of Ig/TCR gene rearrangements (2%) was significantly lower (P = 0.041) as compared to the other patient groups (Ͻ5 years, 5-15 years and Ͼ60 years). A second significant association was observed between the expression of B cell-associated markers (CD19 and/or CD20) and the presence of Ig/TCR gene rearrangements (P = 0.014). All other immunophenotypic parameters, including expression of T cell-associated markers (CD2/CD4/CD5/CD7) and TdT, were not significantly related to the presence or absence of Ig/TCR gene rearrangements. Finally, no significant correlation was found between sex or FAB subtype and the occurrence of Ig/TCR gene rearrangements. 
a Given are the numbers of deleted nucleotides from the germline sequence of the involved gene segments and the sequence of the N-regions. b The most recent nomenclature was used to designate IGH gene segments.
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c Complex IGK gene rearrangement: The V3-20 gene segment was coupled to J3, followed by the intronic sequence till the RSS of J4. The J4 gene segment itself was absent, the RSS of J4 was followed by another junctional region and Kde. d This is the only AML patient who also had a fusion gene transcript. e The four TCRG gene rearrangements were only detectable by PCR, not by Southern blotting, implying that they were derived from small subclones. f NA, Sequence information not available.
Analysis of RAG1 and RAG2 expression levels
BM and/or PB of seven AML patients with Ig and/or TCR rearrangements could be analyzed for the level of RAG1 and RAG2 transcripts, in order to investigate whether the occurrence of Ig/TCR gene rearrangements in AML was related to RAG expression levels. Results were compared with the expression levels in nine AML patients without Ig/TCR gene rearrangements. ALL patients with monoclonal (n = 10) or oligoclonal (n = 10) rearrangements were used as positive control groups. Results showed that the RAG1 expression was significantly lower than the RAG2 expression in all four groups (P Ͻ 0.05). However, the RAG1 and RAG2 expression levels were not significantly different between the AML patients with rearranged Ig/TCR genes and the AML patients with germline Ig/TCR genes. Furthermore, the RAG1 and RAG2 expression levels were significantly lower in AML with rearranged Ig/TCR genes than in ALL with monoclonal rearrangements and ALL with oligoclonal rearrangements (P Ͻ 0.0001). RAG1 and RAG2 expression levels did not differ significantly between the two latter control groups. Finally, the expression levels of RAG1 and RAG2 were not significantly different between BM and PB samples of the AML patients ( Figure 3 ).
Discussion
In our study, 105 consecutive AML patients were investigated by RT-PCR for the presence of fusion gene transcripts, which were identified in 17 AML patients (16%), including four of the 24 children (16.5%). This percentage in childhood AML is rather low compared to the frequencies published by other groups, 30 which may be caused by the relatively small number of children analyzed. In agreement with the findings of Raimondi et al, 30 we found that t(8;21) is the most common aberration in pediatric patients. In the adult AML patients, we identified 13 fusion gene transcripts (16%). Although in adult AML the frequency of the investigated fusion gene transcripts is considered to be 20-25%, age-related differences can be observed. In AML patients above 60 years of age at diagnosis, the total frequency of detectable fusion genes is Ͻ10%. 31 In our study, 27 of the 81 adults belonged to this older age group and only one of them (4%) contained a fusion gene transcript (inv (16) ) as detected by RT-PCR; this might partly explain the lower overall percentage in this study. Consequently, the frequency of fusion transcripts in the adult AML patients below 60 years was 22% (12/54). Two adult AML patients contained BCR-ABL transcripts, which is a remarkable finding because in most AML reports the frequency of t(9;22) is Ͻ1%.
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Figure 2
PCR heteroduplex analysis of cross-lineage rearrangements in AML. Samples containing PCR products were subjected to heteroduplex PCR analysis, separated in a 6% polyacrylamide gel and visualized by ethidium bromide staining. (a) Clonal V␦2-J␦1 and D␦2-D␦3 homoduplexes were seen in patient P-08 and P-20, respectively. The VIII-Kde combination showed a large clonal product in P-08. Analysis with V␥II family-specific primers in combination with J␥1.3/2.3 primers shows homoduplexes in three patients. (b) Using DH3 primers in combination with JH consensus primers, clonal PCR products were found in patients A-16, A-34 and A-62.
Figure 3
RAG1 and RAG2 gene mRNA levels in AML and ALL as assessed by RQ-PCR. BM (circles) and/or PB (triangles) samples of AML with or without rearranged Ig/TCR genes were analyzed for their levels of RAG1 and RAG2 transcripts. Monoclonal and oligoclonal ALL were used as positive controls.
Leukemia
Cross-lineage Ig/TCR gene rearrangements were investigated in 95 out of the 105 AML patients. Southern blot analysis of the IGH, IGK and TCRD genes showed that clonal rearrangements were found in five, one and three cases, respectively, corresponding to seven different patients. These frequencies are somewhat lower than those found by other groups (Table 2) . [9] [10] [11] [12] In our previous study, we found IGH, IGK and TCRD gene rearrangements in 13%, 2%, and 4% of patients, respectively. In six of the seven cases of our new patient series, we could identify the rearrangements with PCR heteroduplex analysis. Sequence analysis of these rearrangements showed that most junctional regions were comparable to what can be found in ALL. Hence, these Ig/TCR gene rearrangements are potentially suitable as PCR targets for MRD analysis.
Previous studies indicate that about 5% of AML cases have TCRG gene rearrangements as detected by Southern blot analysis. 9, 10 In our series, 95 AML patients were prescreened by PCR heteroduplex for this target: four clonal rearrangements were identified in a total of three patients. However, no rearranged bands could be found by subsequent Southern blot analysis, probably because the clonal PCR products derived from small leukemic subclones. We therefore assume that these TCRG gene rearrangements are not useful as PCR-MRD targets in AML.
To get more insight into the type of Ig/TCR gene rearrangements that occur in AML, we additionally performed PCR heteroduplex analysis in five AML patients, who were shown to contain IGH (n = 4), TCRD (n = 2), and/or TCRG (n = 2) rearrangements by Southern blot analysis in our previous study. 9 Looking at the IGH locus of both patient groups, 10 of the 11 gene rearrangements were incomplete D H -J H joinings (Table 1) . Only one concerned a complete V H -D H -J H recombination, involving the most downstream V H 6-1 gene segment. Virtually all used D H gene segments (10/11; 91%) belonged to the more downstream D H segments. Analysis of the J H gene segment usage showed a more frequent usage of the J H 4 and J H 6 gene segments, which is also the case in normal lymphocytes and B cell malignancies. The predominance of incomplete D H -J H rearrangements together with the frequent usage of the more downstream DH gene segments fits with immature rearrangements as also found in T-ALL. 27 The only IGK rearrangement identified comprised a complex IGK gene rearrangement, which is rare in B cell malignancies (AW Langerak, unpublished results), and has never been described in normal cells before. This complex rearrangement can only be explained by a multistep process. 32 Irrespective of the subclonal origin of the four TCRG gene rearrangements in the random series of 95 AML patients, it is remarkable that the Only reports on large patient series (n Ͼ 50) were used for this Table. NT, not tested.
total of seven TCRG rearrangements all included one of the four most downstream V␥ gene segments. Finally, the frequency of TCRD gene rearrangements is in line with previous reports. 33, 34 Two TCRD rearrangements concerned the immature incomplete V␦2-D␦3 and D␦2-D␦3 rearrangements; in one patient biallelic D␦2-J␦1 rearrangements were detected and another patient contained a complete V␦2-D␦3-J␦1 rearrangement. This is in contrast to precursor-B-ALL, where TCRD gene rearrangements generally do not involve J␦1 segments. Thus, the TCRD gene rearrangements in AML are rather heterogeneous.
Overall results show that only in one patient (P-20), a PCRdetectable chromosome aberration coexisted with an Ig/TCR gene rearrangement. Therefore, cross-lineage Ig/TCR gene rearrangements in AML might be useful as supplementary MRD-PCR targets in addition to leukemia-specific chromosome aberrations.
As the frequency of PCR-detectable Ig/TCR rearrangements in AML appeared to be low (Ͻ10%), we aimed to analyze whether their presence can be predicted by relatively high expression levels of RAG1 and RAG2 transcripts, enzymes involved in the rearrangement processes. Our results obtained by RQ-PCR analysis showed that the expression levels of both RAG1 and RAG2 mRNA were comparable between AML patients with and without Ig/TCR gene rearrangements. Although these genes must have been expressed in an earlier phase of AML development, they might have been downregulated at the time of diagnosis. Apparently, RAG1 and RAG2 mRNA levels are not a straightforward tool for the prediction of Ig/TCR gene rearrangements in AML (Figure 3) .
We also checked for associations between Ig/TCR gene rearrangements and patient and disease characteristics, such as immunophenotype, especially the presence of B and T cellassociated markers. Our results showed that the frequency of Ig/TCR gene rearrangements (2%) in the patient group of 16 to 60 years was significantly lower as compared to other age groups. Another interesting finding was the significant association between positivity for B cell-associated markers (CD19 and/or CD20) and the presence of Ig/TCR gene rearrangements. Importantly, no significant association between TdT expression and the presence of Ig/TCR gene rearrangements was seen, although most Ig/TCR rearranged AML did have inserted nucleotides at their junctional region. Most probably, Ig/TCR gene rearrangements represent early post-oncogenic events, whereas the enzymatic activity of V(D)J recombinase (RAG1 and RAG2) and TdT is already downregulated at the time of diagnosis.
In conclusion, this study shows that fusion gene transcripts and Ig/TCR gene rearrangements are generally complementary, but relatively infrequent PCR targets for MRD detection in AML. Investigation of Ig/TCR gene rearrangements in AML patients is probably not realistic in a routine setting, because this provides only a limited number of additional MRD-PCR targets, and its presence can not be predicted by RAG mRNA expression. Previous studies on Ig/TCR gene rearrangements used Southern blot analysis and might have given an overestimation of the number of MRD-PCR targets, since not all rearrangements found by Southern blotting can be identified by PCR analysis.
In this study, only approximately 20% of the AML patients had a reliable MRD-PCR target (16% with chromosome aberrations and 6% with PCR-identified Ig/TCR gene rearrangements). Consequently, the detection of MRD in the majority of AML patients needs another reliable and sensitive technique. Multiparameter flow cytometric immunophenotyping is the best suited alternative, since 70 to 80% of AML patients show an aberrant or infrequent immunophenotype at diagnosis. 1, 35 
